Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 747 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Cancer in children and young people: how far we’ve come September 29, 2021 Reunión anual de la American Society of Clinical Oncology de 2023:... June 2, 2023 Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... September 16, 2021 Load more HOT NEWS How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced... EMA Recommends Extension of Indications for Datopotamab Deruxtecan FDA Approves Nirogacestat for Desmoid Tumours
